Chapter 1: Executive Summary

• Scope and Methodology
• In Vitro and In Vivo Tests for Early CVD
• Size and Growth of the Market
• Market Trends

Chapter 2: Introduction

• 21st Century Disease Management Paradigm: Cardiovascular Tests, Genes, Imaging, and Bioinformatics
• The Pros and Cons of Early Diagnosis
• Point of View

Chapter 3: Trends and Issues

• Background and Epidemiology
  • Market Population Trends in Major World Markets
  • World Cardiac Disease Demographics
  • North America
  • Africa and Asia
  • Latin America
  • Europe
• Specific Disease Statistics
  • Deep Vein Thrombosis
  • Coronary Artery Disease
  • Hypertension
  • Congestive Heart Failure
  • Stroke
• Human Genomics in Early CVD Assessment
• Home Telemedicine Initiatives
• Bioinformatics and Risk Assessment
• Technology, Patient Outcomes, and Reimbursement Issues

Chapter 4: In Vitro Tests for Early CVD Diagnosis

• Market Overview
  • Total Market
  • Geographic Analysis
  • Market Penetration
  • Cell Necrosis Enzymes
  • Coagulation Factors
  • Homocysteine
  • D-Dimer
  • High-Sensitivity C-Reactive Protein and Inflammation Markers
  • Lipids
  • Specific Enzymes and Proteins
  • Genes
  • Viral Infections
• Commercial Outlook

Chapter 5: In Vitro Company Profiles

• Agen Biomedical Ltd
• American Biogenetic Sciences Inc
• Axis-Shield Diagnostics Ltd
• Biopool International Inc (see Xtrana Inc)
• Biosite Diagnostics Inc
• Cholestech Corp
• Competitive Technologies Inc
• CompuCyte Corp
• Corgenix Medical Corp
• CV Technologies Inc
• Dade Behring Inc
• diaDexus Inc
• Ischemia Technologies Inc
• LipoMed Inc
• Myriad Genetics Inc
• Sigma Diagnostics
• Spectral Diagnostics
• SYN X Pharma Inc
• Third Wave Technologies Inc
• Xtrana Inc

Chapter 6: In Vivo Diagnostics—Imaging and Assessment DEVICES

• Background
  • Coronary Artery Disease
  • Peripheral Vascular Disease
• Market Overview
• Electrocardiography, Stress Tests, and Holter Monitors
• Heart Rate, Blood Flow, Hemodynamics, and Electrophysiology
• Nuclear Cardiology—X-ray Angiograph
• Ultrasound
• Magnetic Resonance Imaging
• Computed Tomography
• Positron Emission Tomography
• Three-Dimensional Imaging
• Contrast Agents
• Commercial Outlook

Chapter 7: In Vivo Company Profiles

• ATL Ultrasound—Advanced Technology Laboratories Inc
• Boston Medical Technologies Inc
• Boston Scientific (see Cardiac Pathways Corp)
• Cambridge Heart Inc
• Cardiac Mariners Inc (see NexRay Inc)
• Cardiac Pathways Corp
• CardioDynamics International Corp
• Deltex Medical, Ltd
• EP MedSystems Inc
• FONAR Corp
• Hypertension Diagnostics Inc
• Imatron Inc
• Itamar Medical Ltd
• NexRay Inc
• Royal Philips Electronics (see ATL Ultrasound—Advanced Technology
• Laboratories Inc)
• SonoSite Inc
• Vital Images Inc
• Volumetrics Medical Imaging

Chapter 8: Conclusions and Strategic Implications

• Early Detection and Cost Savings
  • Conclusion
  • Implication
• In Vitro Panels Remain Imperative
  • Conclusion
  • Implication
• The Role of In Vivo Testing
  • Conclusion
  • Implication
• Telehealth
  • Conclusion
  • Implication
• Nature of Competitors
  • Conclusion
  • Implication
• Cost-Benefit Analyses
  • Conclusion
  • Implication
• Consumerism
  • Conclusion
  • Implication

List of Exhibits
Chapter One: Executive Summary
Table 1-1: Worldwide Market for Selected Cardiac In Vitro Diagnostics: 2000-2005
Table 1-2: Worldwide In Vivo Cardiac Diagnostic Procedures by Type: 2000-2005
Chapter Three: Trends and Issues
Table 3-1: Selected Genetic Tests and Therapeutic Targets
Table 3-2: Selected Companies Developing Cardiovascualar Genomic
Chapter Four: In Vitro Tests for Early CVD Diagnosis
Table 4-1: Selected In Vitro Diagnostic Markers for CVD
Table 4-2: Selected CVD Drug Targets
Table 4-3: Worldwide Market for Selected Cardic In Vitro Diagnostics: 2000-2005
Figure 4-1: Worldwide Market for Cardiac In Vitro Diagnostics, Market Share by Test Type: 2000
Figure 4-2: Worldwide Market for Cardiac In Vitro Diagonistics, Market Share by Test Type: 2005
Figure 4-3: Worldwide Market for Cardiac In Vitro Diagnostics, Revenue Distribution by Region: 2005
Figure 4-4: Technology Penetration Forecast for Cardiac In Vitro Diagnostics: 2000-2010
Table 4-4: Reported Serum Marker Cut-Off Values
Table 4-5: Cut-off, Percentile, and Coefficient of Variation for Leading Troponin Assays
Chapter Six: In Vivo Diagnostics—Imaging and Assessment Devices
Table 6-1: In Vivo CVD Test Techniques
Table 6-2: Worldwide In Vivo Cardiac Diagnostic Procedures by Type: 2000-2005
Figure 6-1: Worldwide Market for Cardiac In Vivo Diagnostics, Market Share by Test Type: 2000
Figure 6-2: Worldwide Market for Cardiac In Vivo Diagnostics, Market Share by Test Type: 2005
Figure 6-3: Technology Penetration Forecast for Cardiac In Vivo Diagnostics 2000-2010